New combo therapy trial aims to rally immune system against HPV cancers
NCT ID NCT04432597
Summary
This early-phase trial is testing a new therapeutic HPV vaccine, given alone or combined with an immunotherapy drug called M7824, in people with cancers linked to HPV. The main goals are to find a safe dose and see if the treatments can stimulate the body's immune system to better fight the cancer. The study includes adults with various advanced or newly diagnosed HPV-positive cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.